Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City. The company develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.
Pfizer initiated early execution of its $2.5B multi-year manufacturing optimization and cost-cutting program, triggering labor union disputes over 330 job cuts (~60% of site staff) and the shuttering of its penicillin production unit in Catania, Sicily, alongside ~150 confirmed layoffs at its Portage, Michigan facility and additional cuts across North Carolina sterile injectables and biologics plants.
Pfizer expanded its multi-year cost-realignment and manufacturing optimization initiatives by an additional $2.5B across R&D and manufacturing, including ~150 job cuts in Portage, Michigan and reductions in North Carolina and Catania, Italy.
Pfizer confirmed an early rollout of its multi-year $2.5B manufacturing optimization initiative, triggering Italian union disputes over 330 job cuts in Catania, Sicily, alongside ~150 confirmed layoffs at its Portage, Michigan facility and additional cuts at North Carolina plants.
Pfizer makes 'business decision' to end trial of autoimmune drug
Pfizer's Tukysa has been cleared for earlier use in the treatment of breast cancer.
Pfizer punts Seagen ADC, further muddying value of the $43B buyout
Pfizer unveiled an additional $2.5 billion in planned cost savings through 2029 as it continues cutting costs and programs.
Pfizer has dropped an obesity asset it acquired from Metsera along with a GIPR-targeting prospect as part of its portfolio pruning.
Pfizer CEO Albert Bourla defended the company's $7 billion bolt-on M&A strategy as peers rush to make larger acquisitions.
Pfizer is cutting an additional $2.5 billion across R&D and manufacturing as part of its ongoing restructuring.
Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M. Reported by Endpoints News on 2026-07-30.
FDA expanded approval of Pfizer/Seagen's Padcev plus Merck's Keytruda combination to muscle-invasive bladder cancer (MIBC), intensifying competitive pressure on AstraZeneca's checkpoint inhibitor.
Pfizer, Innovent GLP-1 drugs clear China insurance hurdle. (Reuters Biopharma.)
Despite an overall survival miss, Leerink Partners said Pfizer’s antibody-drug conjugate showed “promising” signals of efficacy in a subgroup of patients who had undergone only one prior line of treatment.
Chairman and Chief Executive Officer
No active job listings. Check back later.